Honeybell Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 06-12-2024
- Paid Up Capital ₹ 0.30 M
as on 06-12-2024
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 1864.44%
(FY 2020)
- Profit 326.81%
(FY 2020)
- Ebitda 389.25%
(FY 2020)
- Net Worth 3830.19%
(FY 2020)
- Total Assets 114.79%
(FY 2020)
About Honeybell Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Parekh, Bhavesh Jain, and Ankit Jain serve as directors at the Company.
- CIN/LLPIN
U74999MH2018PTC316948
- Company No.
316948
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Honeybell Pharma Private Limited offer?
Honeybell Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Injectable Products, Anti Infective Drugs & Medicines, Antibiotic Injection, Anti Infective Agent, Hair Growth Medicine, Sexual Wellness Products, Fertility Enhancer, Cardiovascular Drugs & Medication, Kidney Drugs.
Who are the key members and board of directors at Honeybell Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Parekh  | Additional Director | 01-Apr-2020 | Current |
| Bhavesh Jain | Director | 12-Nov-2018 | Current |
| Ankit Jain | Additional Director | 29-Sep-2020 | Current |
Financial Performance of Honeybell Pharma.
Honeybell Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1864.44% increase. The company also saw a substantial improvement in profitability, with a 326.81% increase in profit. The company's net worth Soared by an impressive increase of 3830.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Honeybell Pharma?
In 2020, Honeybell Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- American Remedies Healthcare Private LimitedActive 4 years 10 months
Sanjay Parekh and Bhavesh Jain are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Honeybell Pharma?
Unlock and access historical data on people associated with Honeybell Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Honeybell Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Honeybell Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
